Rituximab-hyperfractionated cyclophosphamide, vincristine, adriamycin and dexamethasone alternating with high-dose cytarabine and methotrexate for aggressive non-Hodgkin lymphoma

Leukemia and Lymphoma

Volumn 53, Issue 4, 2012, Pages 725-727

  Muringampurath John, Disni ^a   Flowers, Christopher R ^a   Toscano, Michael ^b   Zhengjia, Chen ^a   Kaufman, Jonathan L ^a   Arellano, Martha ^a   Bernal Mizrachi, Leon ^a   Heffner, Leonard T ^a   Lechowicz, Mary Jo ^a   McLemore, Morgan ^a   Winton, Elliott ^a   Jaye, David L ^b   Lonial, Sagar ^a   Khoury, Hanna Jean ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Department of Pathology   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; IMMUNOGLOBULIN HEAVY CHAIN; METHOTREXATE; PREDNISONE; RITUXIMAB; VINCRISTINE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; B CELL LYMPHOMA; BURKITT LYMPHOMA; CONFIDENCE INTERVAL; DRUG MEGADOSE; FLUORESCENCE; FOLLICULAR LYMPHOMA; FOLLOW UP; HUMAN; IMMUNOHISTOCHEMISTRY; IMMUNOPHENOTYPING; IN SITU HYBRIDIZATION; KARYOTYPING; LETTER; LYMPHATIC LEUKEMIA; LYMPHOBLASTOMA; MANTLE CELL LYMPHOMA; MORTALITY; NONHODGKIN LYMPHOMA; OVERALL SURVIVAL; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; WORLD HEALTH ORGANIZATION;

ADULT; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHEMICAL FRACTIONATION; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOXORUBICIN; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHOMA, NON-HODGKIN; MIDDLE AGED; TREATMENT OUTCOME; VINCRISTINE; YOUNG ADULT;

EID: 84859025266     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.3109/10428194.2011.619019     Document Type: Letter

References (14)

1. Coiffi er B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diff use large-B-cell lymphoma. N Engl J Med 2002;346: 235-242.
2. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diff use large-B-cell lymphoma: a randomised controlled trial by the MabTh era International Trial (MInT) Group. Lancet Oncol 2006;7:379-391.
3. Sehn LH, Berry B, Chhanabhai M, et al. Th e revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diff use large B-cell lymphoma treated with R-CHOP. Blood 2007;109:1857-1861.
4. Sweetenham JW, Pearce R, Taghipour G, et al. Adult Burkitt' s and Burkitt-like non-Hodgkin ' s lymphoma-outcome for patients treated with high-dose therapy and autologous stem-cell transplantation in fi rst remission or at relapse: results from the European Group for Blood and Marrow Transplantation. J Clin Oncol 1996;14: 2465-2472.
5. Nademanee A, Molina A, O' D onnell MR, et al. Results of high-dose therapy and autologous bone marrow/stem cell transplantation during remission in poor-risk intermediate- and high-grade lymphoma: international index high and high-intermediate risk group. Blood 1997;90:3844-3852.
6. Fisher RI, Gaynor ER, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin ' s lymphoma. N Engl J Med 1993;328: 1002-1006.
7. Aguiar Bujanda D, Aguiar Morales J, Bohn Sarmiento U, et al. Clinical experience with biweekly CHOP plus rituximab chemoimmunotherapy for the treatment of aggressive B-cell non- Hodgkin lymphoma. Clin Transl Oncol 2009;11:604-608.
8. Pfreundschuh M, Schubert J, Ziepert M, et al. Six versus eight cycles of bi-weekly CHOP-14 with or without rituximab in elderly patients with aggressive CD20+ B-cell lymphomas: a randomised controlled trial (RICOVER-60). Lancet Oncol 2008;9:105-116.
9. Th omas DA, Cortes J, O 'B rien S, et al. Hyper-CVAD program in Burkitt ' s-type adult acute lymphoblastic leukemia. J Clin Oncol 1999;17:2461-2470.
10. Romaguera JE, Fayad L, Rodriguez MA, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantlecell lymphoma with rituximab plus hyper-CVADalternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005;23:7013-7023.
11. Th omas DA, Faderl S, O 'B rien S, et al. Chemoimmunotherapy with hyper-CVAD plus rituximab for the treatment of adult Burkitt and Burkitt-type lymphoma or acute lymphoblastic leukemia. Cancer 2006;106:1569-1580.
12. Sabattini E, Bacci F, Sagramoso C, et al. WHO classifi cation of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 2010;102:83-87.
13. Cheson BD, Horning SJ, Coiffi er B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin ' s lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244.
14. Lonial S, Arellano M, Hutcherson D, et al. Results of a clinical phase I dose-escalation study of cytarabine in combination with fi xed-dose vinorelbine, paclitaxel, etoposide and cisplatin for the treatment of relapsed/refractory lymphoma. Leuk Lymphoma 2006;47: 2155-2162.